DNA methylation-based biomarkers and prediction models for the survival of patients with colorectal cancer: systematic review and external validation study

Abstract

ABSTRACTObjectivesTo identify existing DNA methylation-based prognostic biomarkers and prediction models for colorectal cancer (CRC) prognosis and to validate them in a large external cohort.DesignSystematic review and external validation study.Data sourceSystematic search in PubMed and Web of Science until October 2022 to identify epigenome-wide studies reporting methylation at CpG sites (CpGs) associated with survival among CRC patients. Validation data were drawn from the 2310 CRC patients of the DACHS study recruited from 22 hospitals in the Rhine-Neckar region in the southwest of Germany.Main outcome measuresOverall survival (OS) in CRC patients.ResultsWe identified 200 unique CpGs and 10 CpG-based prognostic models derived from 15 studies. In the external validation analysis, 1252 of 2310 patients died during follow-up (median 10.4 years). Thirty-nine CpGs (20%) and five prognostic models (50%) were independently associated with overall survival after adjustment for clinical variables. The five models had unsatisfactory discrimination ability, with area under the receiver operating characteristic curves at five years ranging from 0.54 to 0.60. The calibration accuracy of the five models using recalibrated baseline survival was also poor, and no relevant added prognostic value to traditional clinical variables was observed. Based on the Prediction Model Risk of Bias Assessment Tool, all models were rated as high risk of bias.ConclusionsOnly 20% of published CpGs associated with survival in CRC patients could be externally validated. So far derived published CpG-based prognostic models for CRC do not seem to be useful for clinical practice.Summary boxWhat is already known on this topicSeveral studies have suggested that DNA methylation biomarkers could have the potential to improve prognostic accuracy for patients with colorectal cancer (CRC), but these studies mostly did not include large-scale external validationMany CpG sites associated with CRC prognosis and prognostic models based on these CpGs have been proposedAn independent study to validate these biomarkers and prediction models is essential for assessing their utility in clinical practice, but has not yet performedWhat this study addsThis external validation study verified the prognostic relevance of a fraction of existing DNA methylation-based prognostic biomarkers for CRCPublished CpG-based prognostic models all performed poorly in our external validation and were rated as at high risk of bias, so they do not seem to be useful for clinical practice